Last reviewed · How we verify
SABA
At a glance
| Generic name | SABA |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
- Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment (NA)
- Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma (PHASE3)
- PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (PHASE3)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
- Receptive Music Interventions During Intradermal Testing in Children (NA)
- Assessment of Traumatic Brain Injury Using Transcranial Magnetic Stimulated Evoked Potentials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SABA CI brief — competitive landscape report
- SABA updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI